Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

There were no significant differences between the two groups in age, sex, diabetic kidney disease, medical history of IHD, systolic and diastolic blood pressures, nephrologist follow-up years, hemoglobin, CRP, uric acid, sodium, potassium, chloride, serum albumin, and intact PTH.Baseline characteristics and comparison of patients who presented with or without uremic nauseaVariableOverall (n = 1536)Nausea− (n = 1306)Nausea+ (n = 230) P valueMale sex [n (%)]1058 (68.9)892 (68.3)166 (72.2)0.2420Diabetic kidney disease [n (%)]663 (43.2)572 (43.8)91 (39.6)0.2321Medical history of IHD [n (%)]288 (18.8)245 (18.8)43 (18.7)0.9817Age (years)67.2 ± 13.067.2 ± 13.267.1 ± 12.10.9116Systolic blood pressure (mmHg)152.1 ± 24.9152.3 ± 24.6151.0 ± 26.30.4939Diastolic blood pressure (mmHg)77.2 ± 14.477.2 ± 14.376.8 ± 14.90.6577Nephrologists follow-up (years)3.69 ± 3.623.70 ± 3.753.62 ± 2.800.7558 Laboratory data Hemoglobin (g/dl)8.77 ± 1.488.78 ± 1.488.67 ± 1.490.2995C-reactive protein (mg/dl)1.27 ± 3.061.34 ± 3.240.92 ± 1.700.0563Urea nitrogen (mg/dl)89.3 ± 26.488.6 ± 26.194.2 ± 27.60.0030Creatinine (mg/dl)9.36 ± 3.189.24 ± 3.1110.0 ± 3.470.0005eGFR (mL/min/1.73 m2)5.20 ± 1.925.26 ± 1.944.88 ± 1.770.0053Uric acid (mg/dl)8.50 ± 2.238.48 ± 2.248.58 ± 2.210.5636Sodium (mEq/L)138.0 ± 4.5138.1 ± 4.5137.5 ± 4.20.0742Potassium (mEq/L)4.60 ± 0.834.61 ± 0.834.55 ± 0.810.2550Chloride (mEq/L)105.0 ± 6.0104.9 ± 6.0105.3 ± 6.40.3366Corrected calcium (mg/L)8.54 ± 0.948.56 ± 0.948.43 ± 0.880.0452Phosphorus (mg/dl)6.15 ± 1.676.11 ± 1.646.37 ± 1.780.0259Albumin (g/dl)3.24 ± 0.593.24 ± 0.593.25 ± 0.570.8696Intact PTH (pg/ml)322.6 ± 250.4320.5 ± 256.7334.2 ± 211.40.5342CTR (%)54.1 ± 6.554.3 ± 6.653.1 ± 6.10.0075 Medications ESA [n (%)]1286 (83.7)1086 (83.2)200 (87.0)0.1498VDRA [n (%)]392 (25.5)357 (27.0)40 (17.4)0.0022CaCO3 [n (%)]528 (34.4)452 (34.6)76 (33.0)0.6447Loop diuretics [n (%)]1071 (69.7)927 (71.0)144 (62.6)0.0108AST-120 [n (%)]308 (20.1)256 (19.6)52 (22.6)0.2936CCB [n (%)]1166 (75.9)990 (75.8)176 (76.5)0.8144RAAS inhibitors1016 (66.2)867 (65.6)159 (69.1)0.2996Other hypertensive drugs701 (45.6)598 (45.8)103 (44.8)0.7776Data are expressed as numbers (%) of patients or mean ± SD IHD ischemic heart disease, eGFR estimated glomerular filtration rate, PTH parathyroid hormone, CTR cardiothoracic ratio, ESA erythropoiesis-stimulating agent, VDRA vitamin D receptor activator, CaCO 3 calcium carbonate, AST-120 an orally administered uremic toxin adsorbent, CCB calcium channel blocker; RAAS renin-angiotensin-aldosterone system

Source: Comparison of patients who presented with or without uremic nausea. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A multicenter, retrospective, cross-sectional study was performed to identify a medication to prevent uremic nausea.

Source: Abstract.

As a result, 1911 patients were excluded from the analysis due to having stage 1 to 4 CKD (45 patients), being ≤19 years old (3 patients), having an uncertain history of ischemic heart disease (IHD) (164 patients) and comorbidity (29 patients), a follow-up period of <3 months or unknown length (819 patients), lack of data regarding medication use in the previous 3 months (254 patients), and insufficient laboratory data (624 patients).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Possible prevention of uremic nausea by vitamin D receptor activators in non-dialysis patients with stage 5 chronic kidney disease

Cross-sectional study · Clinical and Experimental Nephrology · 2016

Original publication title

Possible prevention of uremic nausea by vitamin D receptor activators in non-dialysis patients with stage 5 chronic kidney disease

Masato Ikeda; Yoshimi Ueda; Yukio Maruyama; Keitaro Yokoyama; Takashi Yokoo; Nobuhiko Joki; Ryoichi Ando; Toshio Shinoda; Daijo Inaguma; Toshihiko Yamaka; Yasuhiro Komatsu; Fumihiko Koiwa; Toshifumi Sakaguchi; Shigeo Negi; Takashi Shigematsu

© The Author(s) 2016

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Use of VDRAs during the predialysis period was the only factor associated with a lower prevalence of uremic nausea, suggesting that VDRAs may prevent uremic nausea in patients with advanced CKD.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Nausea is a major uremic symptom and a frequent indication for starting dialysis. However, preventive medication for uremic nausea has not yet been identified. Vitamin D receptor activators (VDRAs) may prevent uremic nausea via their pleiotropic actions. The objective of this study was to explore whether VDRA administration during the predialysis period is associated with a reduced prevalence of uremic nausea just prior to beginning dialysis.

Source: Background

Abstract: What methods does the paper describe?

A multicenter, retrospective, cross-sectional study was performed to identify a medication to prevent uremic nausea. Patients with stage 5 CKD who were followed-up over 3 months were included. The primary outcomes examined were the prevalence of uremic nausea, congestive heart failure (CHF), and intractable edema at dialysis commencement. The predictor variable was VDRA use during the predialysis period.

Source: Methods

Abstract: Results

One thousand five hundred and thirty six patients who had just begun dialysis in nine Japanese facilities between January 2006 and October 2013 were included. Two hundred and thirty (15.0%) patients had commenced dialysis because of uremic nausea, and three hundred and ninety two (25.5%) patients had been using VDRAs before initiating dialysis. Logistic regression analysis showed that, among the medications examined in this study, only VDRA use was independently associated with a lower frequency of uremic nausea (OR 0.512, 95% CI 0.347 to 0.738, P = 0.0003).

On the other hand, CHF and intractable edema were not associated with VDRA administration.

Source: Results

Abstract: Conclusion

Use of VDRAs during the predialysis period was the only factor associated with a lower prevalence of uremic nausea, suggesting that VDRAs may prevent uremic nausea in patients with advanced CKD.

Source: Conclusion
Authors’ abstract

Background

Nausea is a major uremic symptom and a frequent indication for starting dialysis. However, preventive medication for uremic nausea has not yet been identified. Vitamin D receptor activators (VDRAs) may prevent uremic nausea via their pleiotropic actions. The objective of this study was to explore whether VDRA administration during the predialysis period is associated with a reduced prevalence of uremic nausea just prior to beginning dialysis.

Methods

A multicenter, retrospective, cross-sectional study was performed to identify a medication to prevent uremic nausea. Patients with stage 5 CKD who were followed-up over 3 months were included. The primary outcomes examined were the prevalence of uremic nausea, congestive heart failure (CHF), and intractable edema at dialysis commencement. The predictor variable was VDRA use during the predialysis period.

Results

One thousand five hundred and thirty six patients who had just begun dialysis in nine Japanese facilities between January 2006 and October 2013 were included. Two hundred and thirty (15.0%) patients had commenced dialysis because of uremic nausea, and three hundred and ninety two (25.5%) patients had been using VDRAs before initiating dialysis. Logistic regression analysis showed that, among the medications examined in this study, only VDRA use was independently associated with a lower frequency of uremic nausea (OR 0.512, 95% CI 0.347 to 0.738, P = 0.0003).

On the other hand, CHF and intractable edema were not associated with VDRA administration.

Conclusion

Use of VDRAs during the predialysis period was the only factor associated with a lower prevalence of uremic nausea, suggesting that VDRAs may prevent uremic nausea in patients with advanced CKD.

Publication and source details

Original title: Possible prevention of uremic nausea by vitamin D receptor activators in non-dialysis patients with stage 5 chronic kidney disease

Masato Ikeda; Yoshimi Ueda; Yukio Maruyama; Keitaro Yokoyama; Takashi Yokoo; Nobuhiko Joki; Ryoichi Ando; Toshio Shinoda; Daijo Inaguma; Toshihiko Yamaka; Yasuhiro Komatsu; Fumihiko Koiwa; Toshifumi Sakaguchi; Shigeo Negi; Takashi Shigematsu

Clinical and Experimental Nephrology · 2016

© The Author(s) 2016https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T08:34:38.044788+00:00

DOI: 10.1007/s10157-016-1355-8 · PMC5648733